NCT06579703View on ClinicalTrials.gov

Ketorolac for Acute Vaso-Occlusive Crisis in Pediatric Sickle Cell Disease

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

July 1, 2027

Study Completion Date

February 15, 2028

Conditions
Sickle Cell DiseaseSickle Cell CrisisVeno-occlusive Disease
Interventions
DRUG

Ketorolac

"Randomized to a single dose of:~Arm A: 15 mg/mL (per mL) Arm B: 30 mg/mL (per mL)"

All Listed Sponsors
lead

Children's Blood and Cancer Center at Dell Children's Medical Center

OTHER

NCT06579703 - Ketorolac for Acute Vaso-Occlusive Crisis in Pediatric Sickle Cell Disease | Biotech Hunter | Biotech Hunter